Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment

Bibliography

• Tracey D, Klareskog L, Sasso EH, Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244–79
   PubMed Web of Science ®Google Scholar
• Kerensky TA, Gottlieb AB, Yaniv S, Au SC. Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf 2012;11:121–39
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res 2012;32:277–9
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Cagnati P, Update upon efficacy and safety of TNF-alpha inhibitors. Expert Opin Drug Saf 2011;11:1–5
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014–22
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627–32
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304–12
   PubMed Web of Science ®Google Scholar
• Tyring S, Gordon KB, Poulin Y, Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719–26
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Segaert S, Lahfa M, Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol 2008;159:1177–85
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Langley RG, Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241–51
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, A trial of etanercept, a recombinant tumor necrosis factor receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253–9
   PubMed Web of Science ®Google Scholar
• Moreland LW, Schiff MH, Baumgartner SW, Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478–86
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586–93
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675–81
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264–72
   PubMed Web of Science ®Google Scholar
• Zeltser R, Valle L, Tanck C, Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: fc fusion protein. Arch Dermatol 2001;137:893–9
   PubMed Web of Science ®Google Scholar
• Papp KA. The safety of etanercept for the treatment of plaque psoriasis. Ther Clin Risk Manag 2007;3:245–58
   PubMedGoogle Scholar
• Murphy FT, Enzenauer RJ, Battafarano DF, David-Bajar K. Etanercept-associated injection-site reactions. Arch Dermatol 2000;136:556–7
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ncbi.nlm.nih.gov/sites/entrez
   Google Scholar
• Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009;21:211–15
   PubMed Web of Science ®Google Scholar
• Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005;34:19–22
   PubMed Web of Science ®Google Scholar
• Keystone EC, Schiff MH, Kremer JM, Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353–63
   PubMed Web of Science ®Google Scholar
• Dore RK, Mathews S, Schechtman J, The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007;25:40–6
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763–9
   PubMed Web of Science ®Google Scholar
• de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:531–5
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lopez MA, Martinez-Taboada VM, Gonzalez-Vela MC, Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol 2007;32:672–4
   PubMed Web of Science ®Google Scholar
• Edwards KR, Mowad CM, Tyler WB. Worsening injection site reactions with continued use of etanercept. J Drugs Dermatol 2003;2:184–7
   PubMedGoogle Scholar
• Papadavid E, Makris M, Dalamaga M, Recall injection-site reactions to etanercept in a patient with psoriasis. Clin Exp Dermatol 2009;34:414–15
   PubMedGoogle Scholar
• Rajakulendran S, Deighton C. Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept. Rheumatology (Oxford) 2004;43:1588–9
   PubMed Web of Science ®Google Scholar
• Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. Arch Dermatol 2006;142:218–20
   PubMed Web of Science ®Google Scholar
• Benucci M, Manfredi M, Demoly P, Campi P. Injection site reactions to TNF-alpha blocking agents with positive skin tests. Allergy 2008;63:138–9
   PubMed Web of Science ®Google Scholar
• Bavbek S, Aydin O, Ataman S, Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization. Allergy 2011;66:1256–7
   PubMed Web of Science ®Google Scholar
• Pichler WJ. Adverse side-effects to biological agents. Allergy 2006;61:912–20
   PubMed Web of Science ®Google Scholar
• Schellekens H. Immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2003;18:1257–9
   PubMed Web of Science ®Google Scholar
• Sauerborn M, Schellekens H. B-1 cells and naturally occurring antibodies: influencing the immunogenicity of recombinant human therapeutic proteins? Curr Opin Biotechnol 2009;20:715–21
   PubMed Web of Science ®Google Scholar
• Christen U, Thuerkauf R, Stevens R, Lesslauer W. Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities. Hum Immunol 1999;60774–90
   Google Scholar
• Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. J Rheumatol 2000;27:2041–4
   PubMed Web of Science ®Google Scholar
• Brion PH, Mittal-Henkle A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999;131:634
   PubMed Web of Science ®Google Scholar
• Misery L, Perrot JL, Gentil-Perret A, Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 2002;146:334–5
   PubMed Web of Science ®Google Scholar
• Silver J, Benacerraf B. Dissociation of T cell helper function and delayed hypersensitivity. J Immunol 1974;113:1872–5
   PubMed Web of Science ®Google Scholar
• Nydegger UE. Immune complex pathophysiology. Ann N Y Acad Sci 2007;1109:66–83
   PubMed Web of Science ®Google Scholar
• Delves PJ, Martin SJ, Burton DR, Roitt IM. Roitt's essential immunology. Wiley-Blackwell; Oxford: 2011
   Google Scholar
• Norman MU, Lister KJ, Yang YH, TNF regulates leukocyte-endothelial cell interactions and microvascular dysfunction during immune complex-mediated inflammation. Br J Pharmacol 2005;144:265–74
   PubMed Web of Science ®Google Scholar
• Kohl J, Gessner JE. On the role of complement and Fc gamma-receptors in the Arthus reaction. Mol Immunol 1999;36:893–903
   PubMed Web of Science ®Google Scholar
• Orito H, Fujimoto M, Ishiura N, Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 cooperatively contribute to the cutaneous Arthus reaction. J Leukoc Biol 2007;81:1197–204
   PubMed Web of Science ®Google Scholar
• Skytta E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2000;18:533–4
   PubMed Web of Science ®Google Scholar
• Delves PJ, Roitt IM. Encylopedia of immunology. Academic Press; London: 1998
   Google Scholar
• Jacysyn JF, Abrahamsohn IA, Macedo MS. Modulation of delayed-type hypersensitivity during the time course of immune response to a protein antigen. Immunology 2001;102:373–9
   PubMed Web of Science ®Google Scholar
• Askenase PW, Atwood JE. Basophils in tuberculin and "Jones-Mote" delayed reactions of humans. J Clin Invest 1976;58:1145–54
   PubMed Web of Science ®Google Scholar
• Richerson HB, Dvorak HF, Leskowitz S. Cutaneous basophilic hypersensitivity: a new interpretation of the Jones-Mote reaction. J Immunol 1969;103:1431–4
   PubMed Web of Science ®Google Scholar
• Kopf M, Abel B, Gallimore A, Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 2002;8:373–8
   PubMed Web of Science ®Google Scholar
• Borras-Blasco J, Gracia-Perez A, Rosique-Robles JD, Urticaria due to etanercept in a patient with psoriatic arthritis. South Med J 2009;102:304–5
   PubMed Web of Science ®Google Scholar